VB-421

Alumis and Acelyrin have entered into a merger agreement, marking a significant consolidation in the biotechnology sector.

Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027.

Acelyrin's lonigutamab Phase 1/2 study update reveals that lower doses administered every four weeks were subtherapeutic for thyroid eye disease (TED).

Acelyrin's lonigutamab demonstrates a potential best-in-class efficacy and safety profile for treating Thyroid Eye Disease (TED), according to updated Phase 2 data.

Acelyrin will present Phase 2 data for subcutaneous Lonigutamab, indicating a potentially best-in-class efficacy and safety profile for Thyroid Eye Disease (TED).